Checkpoint Inhibitor Refractory Cancer Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Checkpoint Inhibitor Refractory Cancer Market is segmented By Therapy (Immune Checkpoint Inhibitors, Combination Therapies, Targeted Therapies), By Cancer Type (Lung Canc ....

Checkpoint Inhibitor Refractory Cancer Market Size

Market Size in USD

CAGR12.1%

Study Period2024 - 2031
Base Year of Estimation2023
CAGR12.1%
Market ConcentrationHigh
Major PlayersBristol-Myers Squibb, Merck, AstraZeneca, F. Hoffmann-La Roche (Genentech), Regeneron Pharmaceuticals
*Disclaimer: Major players are listed in no particular order.
*Source: Coherent Market Insights
setting-icon
Want to purchase customized report?
please let us know !

Checkpoint Inhibitor Refractory Cancer Market Analysis

The checkpoint inhibitor refractory cancer market is estimated to be valued at USD 37.7 Bn in 2024 and is expected to reach USD 94.2 Bn by 2031, growing at a compound annual growth rate (CAGR) of 12.1% from 2024 to 2031. This market comprises revenue generated from drugs being administered to treat cancer that has become non-responsive or resistant to checkpoint inhibitor therapies such as anti-PD-1 and anti-CTLA-4 drugs.